Print this page    •   Back to Web version of article

Medical News
Glaxo-Vertex Study Tests Anti-HIV Drugs

May 17, 2006

On Tuesday, GlaxoSmithKline PLC (GSK) and Vertex Pharmaceuticals Inc. said early results from a clinical study show their HIV drug Lexiva is comparable to Abbott Laboratories Inc.'s combination drug Kaletra. The study's 887 patients received twice a day either Lexiva (700 mg) along with ritonavir (100 mg), the active ingredient in Abbott's Norvir, or Kaletra (400 mg) with ritonavir (100 mg). Once a day, patients in both groups received abacavir (600 mg) and lamivudine (300 mg), the active ingredients in GSK's HIV drugs Ziagen and Epivir. After 48 weeks, 73 percent of Lexiva patients achieved suppression of HIV replication, compared to 71 percent of the Kaletra patients, according to the study.

Back to other news for May 17, 2006

Excerpted from:
Associated Press

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.